http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
Hereditary spherocytosis is an inherited hemolytic anemia characterized by anemia, jaundice and splenomegaly. The disease is common in northern Europeans but relatively rare in Korea. Growth retardation is an unusual complication in patients with hereditary spherocytosis. Recently, we experienced a 16-year-old female patient with hereditary spherocytosis associated with growth retardation. She was 137㎝ tall, weighed 30.5㎏ (for 16-year-old Korean girls, the third percentile value of height is 147.6㎝ and that of weight is 40.86㎏) and had a bone age of less than 13 years.
Sixteen adult patients with acute myelogenous leukemia received TAD induction chemotherapy consisting of 7day courses of 6-thioguanine (100mg/m^2, every 12hours) and ara-C (100mg/m?^2, daily), and 3-day courses of daunorubicin (45mg/m^2, daily). The patients who didn't achieve complete remission after the first course of TAD received an additional course of a modified TAD consisting of 5-day courses of 6-thioguanine and ara-C, and 2-day courses of daunorubicin. Drug doses were identical to those used in the first course of TAD. Patients who achieved complete remission after the first or the second course of TAD received an alternating maintenance chemotherapy with are-C/6-thioguanine and are-C/daunorubicin (maximum eight courses). Twelve patients (75%) achieved complete remission Median remission duration was 13 months and median survival 13 months. Bone marrow was profoundly depressed in most patients after TAD. Other toxicities of TAD were anorexia, nausea, vomiting headache, alopecia, stomatitis, diarrhea, hepatotoxicity and skin disooloration. No substantial cardiac, renal or neurological toxicity was observed. These results indicate that TAD regimen is effective in the treatment of acute myelogenous leukemia.